4h-(1,3)oxazino(3,2-d)(1,4)benzodiazepine-4,7(6h)-diones

ABSTRACT

OXAZINOBENZODIAZEPINES OF THE FORMULA II:   2-(R8-CH2-),3-R8,6-R7,7-(R6=),8-R5,12B-(R3,R4-PHENYL),   R1,R2-6,7-DIHYDRO-4H-(1,3)OXAZINO(3,2-D)   (1,4)BENZODIAZEPIN-4-ONE   WHEREIN R1, R2, R3 AND R4 ARE HYDROGEN, LOWER-ALKYL, LOWER-ALKOXY, HALOGEN, -CF3, -NO2 OR -CN, WHEREIN R5 IS HYDROGEN, LOWER-ALKYL OR BENZYL, WHEREIN R6 IS OR LOWER-ALKOXY, AND WHEREIN R8 IS HYDROGEN, LOWER-ALKYL OR PHENYL, ARE PREPARED BY REACTING 5-PHENYL-3H-1,4BENZODIAZEPIN-2(1H)-ONES OF FORMULA I:   1-R5,2-(R6=),3-R7,5-(R3,R4-PHENYL),R1,R2-   1,2-DIHYDRO-3H-1,4-BENZODIAZEPINE   WHEREIN R1, R2, R3, R4, R5, R6 AND R7 ARE DEFINED AS ABOVE, WITH AN ACYL HALIDE IN THE PRESENCE OF A BASE OR WITH A DIKETENE. THE NEW PRODUCTS ARE ESSENTIALLY SEDATIVES AND TRANQUILIZERS USEFUL FOR TREATMENT OF MAMMALS.

United States Patent US. Cl. 260239.3 25 Claims ABSTRACT OF THE DISCLOSURE Oxazinobenzodiazepines of the Formula II:

wherein R R R and R are hydrogen, lower-alkyl, lower-alkoxy, halogen, CF NO or CN, wherein R is hydrogen, lower-alkyl or benzyl, wherein R is oxygen or sulfur, wherein R is hydrogen, lower-alkyl or lower-alkoxy, and wherein R is hydrogen, lower-alkyl or phenyl, are prepared by reacting 5-phenyl-3H-1,4- benzodiazepin-2( 1H) ones of Formula I:

2 8 1 R1 R1 I 3 Sok H *N R2 6 Rag R4 CROSS REFERENCE TO RELATED APPLICATION This application is a continuation-in-part of application Ser. No. 760,963, filed Sept. 19, 1968 and now abandoned.

BACKGROUND OF THE INVENTION Field of the invention The present invention is concerned with new organic compounds and more particularly with novel oxazinobenzodiazepines and a process for the production thereof.

ice

SUMMARY OF THE. INVENTION The novel compounds and the process of production thereof can be illustratively represented by the following formulae:

wherein R R R and R are selected from the group consisting of hydrogen, alkyl and alkoxy of 1 to 6 carbon atoms, inclusive, halogen, CF NO and CN; wherein R is selected from the group consisting of hydrogen, alkyl defined as above, and benzyl; wherein R is selected from the group consisting of =0 and =8; wherein R is selected from the group consisting of hydrogen, alkyl defined as above, and alkoxy as defined above; and wherein R is selected from the group consisting of hydrogen, alkyl defined as above, and phenyl.

DESCRIPTION OF THE PREFERRED EMBODIMENT Examples of alkyl of 1 to 6 carbon atoms, inclusive, are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert butyl, pentyl, Z-methylbutyl, neopentyl, hexyl, Z-methylpentyl, 3-methylpentyl, and the like.

Examples of alkoxy of 1 to 6 carbon atoms, inclusive, are methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec.- butoxy, pentyloxy, hexyloxy, and the like.

Halogen herein defined consists of fluorine, chlorine, bromine and iodine.

The process of this invention comprises: treating a selected 5-phenyl-3H-l,4 benzodiazepin 2(1H) one of Formula I with a diketene, either by direct addition or produced in situ, i.e., by the addition of acyl halides, e.g., acyl chloride, acyl bromide or less desirably, acyl iodide and a strong base, e.g., triethylamine. In general, higher yields are obtained by the acyl halide and base method.

protects the mice from convulsions induced by administration of 85 m./kg. pentylene tetrazole. Monkeys at a dosage of 10 rug/kg. of Ha have sharply decreased wakefulness. Cats at a dosage of 1.6 mg./kg. of IIa have i-ncoordinated muscular movement (ataxia) and at a dosage of 2 mg./kg. of IIa are completely relaxed.

The novel compounds II in dosages of 0.5 to 20 mg./ kg. act as good tranquilizers, sedatives and anti-convulsants and can be used in birds and mammals when needed, e.g., for minor veterinary operations, tranquilization during transport of animals by airplane, ship, train, truck and so on. Administration to cattle, horses, dogs, cats, or the like, or zoo animals on long voyages, in a quantity between 0.5 to 20 mg./ kg. of body weight produces sedation and tranquilization and thereby reduces losses of valuable animals due to anxiety, over-excitement and fighting among the caged animals.

The novel compounds of Formula II can be administered to mammals and birds by both oral and parenteral routes in order to produce their pharmacological efiects. [For oral administration, unit dosage forms such as tablets, capulses,- powders, granules, syrups, elixirs and the like containing the appropriate amount for treatment are used. For tablets, common pharmaceutical carriers such as starch, lactose, kaolin, dicalcium, phosphate and the like are employed. Powders may also be used in gelatin capsules with or without carriers such as methylcellulose, magnesium stearate, calcium stearate, talc and the like. For fluid preparations, these compounds may be dissolved or suspended in aqueous alcoholic vehicles with or without buffering agents and with flavoring mixtures.

Starting materials of Formula I and the preparation thereof are disclosed particularly in US. Patents 3,371,085 and 3,296,249, and in L. H. Sternbach et al., Drugs Affecting the Central Nervous System, Medicinal Research Series, vol. 2, chapter 6, pp. 237-264, 1968, Dekker. Representative starting materials comprise:

-phenyl-3H-1,4-benzodiazepin-2 1H) one; 7-chloro-5-pheny1-3H-1,4-benzodiazepin-2 1H) one; 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin- 2( 1H) one; 7-bromo-5-phenyl-3H-1,4-benzodiazepin-2( 1H) one; 7, 8-dimethyl-5-pheny1-3H-1,4-benzodiazepin-2 1H one; 7-chloro-5- (p-chlorophenyl) 3H-1 ,4-benzodiazepin- 2( 1H) one; 7 ,9-dimethyl-5 phenyl-3 H-1,4-benzodiazepin-2( 1H) one; 7,9-dichloro-5-phenyl-3H-1,4-benzodiazepin-2( 1H) -one; 7-bromo-5-(p-tolyl)-3H-1,4-benzodiazepin-2(1H)-one; 7-chloro-3 methyl-S-phenyl-3 H-l ,4-b enzodiazepin- 2 lH) one; 6-chloro-1methyl-S-phenyl-SH- 1,4-benz0diazepin- 4 5- (p-chlorophenyl) 3 H-1,4-benzodiazepin-2 1H) one; 6-chloro-5-phenyl-3H-1,4-benzodiazepin-2( 1H) one; 9-chloro-5-phenyl-3 H-1,4-benzodiazepin-2 1H) one; 7-hexyl-5-phenyl-3H-1,4-benzodiazepin-2( 1H) one; 8-chloro-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one; 7-chloro-5 (m-fluorophenyl) 3 H- 1 ,4-b enzodiazepin- 2( 1H) one; 1benzy1-7-chloro-5-phenyl-3 H-1,4-benzodiazepin- 2 1H one; 7-chloro-5-phenyl-3 methoxy-3 H-1,4-b enzodiazepin- 2 1H) one; 7-chloro-1-ethyl-5-phenyl-3H-1,4-benzodiazepin- 2 1H one 9-methyl-5-phenyl-3H-1,4-benzodiazepin-2 1H) one; 7-chloro-5- (p-fluorophenyl) -3H-1,4-benzodiazepin- 2(1H)-one; 7chloro-S-phenyl-S-methoxymethyl-1,4-benzodiazepin- 2 1H one; 7-chloro-5-(m-tolyl)-3H-1,4-benzodiazepin-2(1H)-one; 7-fluoro-1-methyl-5-phenyl-3H-1,4-benzodiazepin- 2 1H) one; 7-chlorol-methyl-S- (p-chlorophenyl) -3H-1,4-benzodiazepin-2 1H) one; 7-chloro-3 butoxy-S-phenyl-3H-1,4-benzodiazepin- 2 1H) one; 7-chloro-3 pentyloxy-S- (m-tolyl) -3H-1,4-benzodiazepin- 2( 1H) one; 7-chl0r0-3 hexyloxy-S- (p-trifluoromethylphenyl) 3I-I- 1,4-benzodiazepin-2 1H) one; 7-chloro-3-ethoxy-5 (p-methoxyphenyl) -3H-1,4-benzodiazepin-2 1H) one;

7-bromo-3-methoxy-5- (p-chlorophenyl)-3H-1,4-benzodiazepin-2 1H) one;

7-chloro-5 (m-methoxyphenyl) -3H-1,4-benz0diazepin- 2'( 1H one; 7-nitro-5-phenyl-3H-1,4-benz0diazepin-2(1H)-one; 7-cyano-5-phenyl-3H-1,4-benzodiazepin-2 1H) one; 7-butoxy-1-benzyl-5- (p-hexyloxyphenyl) 3H-l ,4-b enzodiazepin-2(1H)-one; 7-trifluoromethyl-5-phenyl-3H-1,4-benzodiazepin- 2 1H one; 7-nitro-1isopentyl-S-phenyl-3H-1,4-benzodiazepin- 2 1H) one; 7-nitro-1-methyl-3 propoxy-S-phenyl-3H-1,4benzodiazepin-2(1H)-one; 7-chloro-5-phenyl-3H-1,4-benzodiazepin-2 1H) thione; 7-chlorol methyl-5-phenyl-3 H-1,4-benzodiazepin- 2 1H) thione;

7 cyan ol-methyl-5aphenyl-3H-1,4-benzodiazepin- 2 1H) one; 7-isopropoxy-1benzyl-S-phenyl-3H-1,4-benzodiazepin- 2( 1H)-one; 7-chloro- 1-benzyl-3 methoxy-S-phenyl-BH-l ,4-benzodiazepin-2( 1H) one,

and the like.

In carrying out the process of this invention by the acyl halide method, a selected 5-phenyl-3H-L4-beuzodiazepin-2(1H) one of Formula I in an inert organic solvent is treated with a selected acyl halide in the presence of a base capable of accepting hydrogen halide. As an inert organic solvent ether (preferred), tetrahydrofuran, methylene chloride, chloroform and the like is used. As a base, organic bases, soluble in the selected solvent, are preferably used, e.g., triethylamine, tributylamine, l-methylpiperidine or the like. However, inorganic bases, e.g., zinc oxide, barium oxide can also be used. The reaction is generally carried out between 0 and 35 C., usually at about room temperature (24-26 C.) or slightly below, at 1820 C. The time to complete the reaction is between 10 and 30 hours. As acyl halides, the bromides and chlorides of alkanoic acids of 2 to 8 carbon atoms, inclusive, and also phenyl-substituted alkanoic acids of 8 to 10 carbon atoms, inclusive, are used providing that these acyl chlorides or bromides have at least two hydrogen atoms at the 2-position in order to be able to form a diketene, thus:

III

wherein R is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, inclusive, and phenyl. Such acyl halides include the chlorides and bromides of acetyl, phenylacetyl, propionyl, butyryl, valeryl, hexanoyl, heptanoyl, isovaleryl, 3-phenylpropionyl and the like. In the preferred embodiment of this invention, to achieve high yields, the molar ratio of Formula I 5-phenyl-3H-benzodiazepin-2(lH)-one to acyl halide to organic base ranges from 1:10:20 to 1:30:60.

After the reaction is terminated the obtained oxazinobenzodiazepine is isolated and purified by conventional methods such as extraction, evaporation, trituration, chromatography and crystallization, and the like.

In carrying out the method using a diketene as described above, as reactant, the selected 5-phenyl-3H-1,4- benzodiazepin-2(lH)-one is refluxed with an excess of the diketene in an inert organic solvent, for example, acetone, benzene, chloroform, and the like. The diketene is defined by Formula III or IIIa above. In the preferred embodiment of this invention, the diketene is used in an excess of 5-15 molar equivalents compared to 1 molar equivalent of the Formula I benzodiazepin-2(1H)-one selected. The reaction is generally carried out at the reflux temperature of the mixture during a period of 1 to hours. The product is isolated and purified by conventional procedures such as extraction, chromatography, trituration, crystallization and recrystallization, and the like.

The following examples are illustrative of the process and product of the present invention, but are not to be construed as limiting.

EXAMPLE 1 11-chl0r0-8,12b-dihydr0-2,8-dimethyl 12b phenyl 4H- [1,3]0xazin0[3,2 d] [1,4]benzodiazepine 4,7(6H)- dione A solution of 78.5 g. (1 mole) of acetyl chloride in 400 ml. of ether was added over a period of 45 minutes to a solution of 7-chloro-1-methyl-5-phenyl-3H 1,4 benzodiazepin-2(1H)-one (28.4 g.; 0.1 mole) and 200 g. (2 moles) of triethylamine in 2 l. of ether while keeping the temperature at C. The mixture was then stirred at room temperature (about 23-25 C.) for a period of 18 hours. It was cooled in ice and 800 ml. each of water and methylene chloride was added. The organic layer was separated and the aqueous layer was extracted once with ether, and the ether washings combined with the organic layer. The total organic extracts were Washed twice with water and then with saturated sodium chloride solution, dried over anhydrous magnesium sulfate and evaporated at 40 C. in vacuo. The resulting yellow solid was washed with water and then triturated with 50 ml. of ice-cold methanol, filtered, washed with two 20-ml. portions of ice-cold methanol, followed by 100 ml. of ether, to give an almost colorless solid (33.3 g.). A 31-g. portion of this solid was recrystallized from 180 ml. of chloroform and 600 ml. of ether to give 22 g. of 11-chloro-8,12b-dihydro 2,8-dimethyl-l2b-phenyl-4H-[ l,3]oxazino[3,2-d]- [l,4]benzodiazepine 4,7(6H) -dione of melting point 182-1835 C.( sintering at 170 C.).

U.V.: A max. 202 (40,600); sh. 241 (18,400).

Analysis.Calcd. for C H ClN O (percent): C, 65.13; H, 4.65; Cl, 9.61; N, 7.60. Found (percent): C, 64.85; H, 4.62; Cl, 9.61; N, 7.58.

6 In the same manner given in Example 1, using 3.05 g. of acetyl bromide, 0.7 g. of 7-chloro-1-methyl-5-phenyl-3H- 1,4-benzodiazepin-2(1H)-one and 5 g. of triethylamine gave 0.4 g. of ll-chloro-8,l2b-dihydro-2,8-dimethyl-12bphenyl-4H-[1,3]oxazino[3,2-d] [l,4]benzodiazepine 4,7- (6H)-dione, identical with the product of Example 1.

EXAMPLE 2 11-chl0r0-8,12b-dihydr0-2,8-dimethyl 12b phenyl 4H- [1,3]0xazin0[3,2 d] [1,4] benzodiazepine 4,7(6H)- dione EXAMPLE 3 11 chloro 8,12b dihydro 2-benzyl-3,12b-diphenyl-8- methyl-4H [1,3]0xazin0[3,2-d] [1,4] benzodiazepine- 4,7(6H)-diam:

(llHa 0 (3113 5 orr2coo1 Cl N C1 OHM d A solution of 3.85 g. (0.025 mole) of phenylacetyl chloride in 10 ml. of ether was added during 10 minutes to a solution of 7-chloro-1-methyl 5 phenyl 3H 1,4- benzodiazepin-2(lH)-one (0.7 g.; 0.0025 mole) and 5 g. (0.05 mole) of triethylamine in 50 m1. of ether, keeping the temperature between 10-15 C. The mixture was then stirred for a period of 18 hours at room temperature (about 2325 C.), cooled in ice, and 20 ml. of water and 10 ml. of methylene chloride were added. The organic layer was separated, Washed with saturated salt solution, dried over anhydrous magnesium sulfate and evaporated. The resulting residue (1.3 g.) was dissolved in 25 ml. of a mixture of 60% (volume) of ethyl acetate and 40% cyclohexane and chromatographed over g. of silica gel using the same solvent mixture as eluant and collecting -ml. fractions. Fractions 3 and 4 were combined and evaporated, and the residue was crystallized from ether to give 0.53 g. of a precipitate in crystalline form. This precipitate was 1l-chloro-8,12b-dihydro-2-benzyl-3,12b-diphenyl '8- methyl-4H-[1,3]oxazino[3,2-d] [1,4] -benzodiazepine-4,7- (6H)-dione of melting point 203207 C.

U.V.: A max. 244 (21,650); sh. 277 (4,550).

Analysis.-Calcd. for 'C H CIN O (percent): C, 73.77; H, 4.84; Cl, 6.81; N. 5.38. Found (percent): C, 73.69; H, 4.96; CI, 6.58; N, 5.56.

EXAMPLE 4 11-chl0r0-8,12b-dihydro-Z-methyl-l2b-phenyl-4H-[1,3] 0xazino[3,2-d] [1,4] benz0diazepine-4,7(6H) -di0ne (A) 11-CHLORO-8,'12b-DIHYDRO-8-BENZYL 2 METHYL- 12b-PHENYL 4H [1,3]OXAZINO[3,2-d] [1,4 BENZO- DIAZEPI'N'E- i, 7 6H) -DIONE In the manner given in Example 1. 1-benzyl-7-chloro- 5 phenyl 3H-1,4-benzodiazepin-2(1H)-one was treated with acetyl chloride in the presence of triethylamine to give 11 chloro 8,12b dihydro 8-benzyl-2-methyl-12bphenyl-4H-[ 1,3]oxazino[3,2-d] [1,4] -benzodiazepine 4,7- (6H)-dione.

(B) 11-CHLO'RO-8,12bDIHYDRO-2-METHYL-12b-PHE'NYL- 4H-[1,3 ]-OXAZINO[3,2-'d] [1,4 BENZODIAZEPINE 4,7

(6H)-DIONE The thus-obtained 11-ch1oro-8,12b-dihydro-8-benzyl-2- methyl-12b-pheny1-4H-[1,3]oxazino[3,2-d] [1,4] benzodiazepine-4,7 6H)-dione was dissolved in ethyl acetate and hydrogenated at 50 p.s.i. hydrogen pressure in the presence of a 10% palladium-on-charcoal catalyst for a period of '6 hours. The reaction mixture was then filtered and evaporated to give 11-chl0r0-8,12b-dihydro-2-methyl-12bphenyl-4H-[1,3]oxazino[3,2-d] [1,4] -benzodiazepine-4,7- (6H)-dione.

EXAMPLE 5 11 chloro 8,12b dihydr-2,8-dimethyl-12b-(p-chlorophenyl) 4H [I,3]0xazino[3,2-d] [1,4] benzodiazepine-4, 7- (6H -di0ne In the manner given in Example 1, 1-methyl-7-chloro- (p-chlorophenyl-BH-1,4-benzodiazepin-2(1H)-one in ether solution was treated with acetyl chloride in the presence of triethylamine to give 11-chloro-8,12b-dihydro-2,8- dimethyl 12b- (p-chlorophenyl) -4H- 1,3 oxazino [3 ,2-d] [1,4]benzodiazepin-4,7(6H)-dione hemihydrate of melting point 181183 C. (eifervescence; sintering 170 C.).

U.V.: A max. 233 (26,000).

Analysis. Calcd. for C H Cl N O -05H O (percent): C, 58.26; H, 4.16; CI, 17.20; N, 6.80. Found (percent): C, 58.69; H, 4.04; Cl, 17.68; N, 6.57.

The hemihydrate was heated at 100 C. and a pressure of 15 mm. of mercury for 72 hours to obtain anhydrous 11 chloro 8,12b dihydro-2,8-dirnethy1-12b-(p-chlorophenyl) 4H-[1,3]-oxazino[3,2-d] [1,4]-benzodiazepine- 4,7 (6H) -dione.

EXAMPLE 6 11 trifluoromethyl-8,12b-dihydr0-2,8-dimethyl-12b-phenyl 4H [1 ,310xazino [3,2-d] [1,4] -benzodiazepine-4,7 (6H -di0ne In the manner given in Example 1, 1-methyl-7-trifiuoro methyl 5 phenyl-3H-1,4-benzodiazepin-2(1H)-one was treated with acetyl chloride in the presence of triethylamine to give 11 trifiuoromethyl-8,12b-dihydro-2,8-dimethyl 12b phenyl-4H-[1,3]oxazino[3,2-d] [1,4]benzodiazepine 4,7(6H)-dione of melting point 134-136" C. (efiervescence U.V.: A max. 203 (36,200); sh. 234 (14,750).

Analysis.-Calcd. for C H F N O (percent): C, 62.68; H, 4.26; F, 14.17; N, 6.96. Found (percent): C, 62.61; H, 4.43; F, 13.38; N, 7.02.

EXAMPLE 7 11 chloro 8,12b-dihydr0-2,8-dimethyl-12b-phenyl-4H- [1,3]oxazin0 [3,2-d] [1,4] benz0diazepin-4 (6H )-0ne-7- thione In the manner given in Example 1, 1-methyl-7-chloro- 5-phenyl-3H-1,4-benzodiazepine-2(1H)-thione was treated in ether solution with acetyl chloride in the presence of triethylamine to give 11-chloro-8,12b-dihydro-2,8-dimethyl 12b phenyl-4H-[1,3]oxazino[3,2-d] [1,4]benzodiazepin 4(6H)-one-7-thione of melting point 197 C. (dec.).

Analysis.Calcd. for C H C1N O S (percent): C, 62.41; H, 4.45; Cl, 9.21; N, 7.28. Found (percent): C, 62.66; H, 4.53; Cl, 9.21; N, 7.32.

EXAMPLE 8 11 cyano 8,1212 dihydr0-2,8-dimethyl-12b-phenyl-4H- [1,3 oxazino [3,2-d] [1,4] benzodiazepine-4J (6H )-di0ne In the manner given in Example 1, 1-methyl-7-cyano- 5 phenyl 3H 1,4-benzodiazepin-2(1H)-one was treated in ether solution with acetyl chloride in the presence of triethylamine to give 11-cyano-8,12b-dihydro-2,8-dimethyl 12b phenyl 4H [1,3]oxazino-[3,2-d][1,4] bgnzodiazepine 4,7(6H)-dione of melting point 152- 1 4 C.

U.V.: sh. 227 (22,900); sh. 260.5 (16,900); A max. 265 (17,400); 269.5 (16,450).

Analysis.-Calcd. for C21H17N3O3 (percent): C, 70.18; H, 4.77; N, 11.69. Found (percent): C, 69.99; H, 5.01; N, 11.83.

EXAMPLE 9 11 nitro 8,12b dihydro-Z,8-dimethyl-12b-phenyl-4H- [1,3]0xazino[3,2 d] [1,4]benz0diazepine 4,7(6H)- dione In the manner given in Example 2, 7.4 g. of l-methyl- 7 nitro-5-phenyl-3H-1,4-benzodiazepin-2(1H)-0ne was treated with 100 g. of diketene at C. for 19 hours to give 11 nitro 8,12b-dihydro-2,8-dimethyl-12b-phenyl- 4H [1,3]oxazino[3,2 d] [1,4]benzodiazepine-4,7(6H)- dione of melting point 196-198 C.

Analysis.Calcd. for C H N O (percent): C, 63.32; H, 4.52; N, 11.08. Found (percent): C, 63.05; H, 4.65; N, 11.09.

EXAMPLE 10 11 chloro-8,12b dihydr0-3 ethyl-8-methyl-2-propyl- 12b phenyl 4H-[1,3]0xazin0[3,2-d] [1,4]benzodiazepin-4,7 (6H -di0ne EXAMPLE 11 11 chloro 8,12b dihydro 2-ethyl-3,8-dimethyl-12bphenyl 4H-[1,3]oxazin0[=3,2-d] [1,4]-benzodiazepine- 4,7(6H)-dione In the manner given in Example 1, 1-methyl-7-chloro- 5-phenyl-3H-1,4-benzodiaZepin-2(1H)-one in ethersolution was treated with propionyl chloride in the presence of triethylamine to give 11-chloro-8,12b-dihydro-2-ethyl- 3,8 dimethyl 12b-phenyl-4H-[1,3]0xazino[3,2-d] [1,4] benzodiazpine 4,7 (6H) dione of melting point 197- 201 C.

U.V.: 203 (38,550); 243 (19,050); sh. 275; sh. 285.

Analysis. Calcd. for C H ClN O (percent): C, 66.58; H, 5.33; Cl, 8.93; N, 7.06. Found (percent): C, 66.52; H, 5.41; Cl, 9.15; N, 6.60.

EXAMPLE 12 8,12b dihydro-Z,8-dimethyl-12b-phenyl-4H- [1,3]oxazino [3,2-d] [1 ,4 benzodiazepine-4J (6H -di0ne In the manner given in Example 1, l-methyl-S-phenyl- 3H 1,4-bcnzodiazepin-2(1H)-one in ether solution was treated with acetyl chloride in the presence of triethylamine to give 8,12-dihydr0-2,8-dimethyl-12b-phenyl-4H [l,3]oxazino[3,2-d] [1,4] benzodiazepine-4,7(6H) dione of melting point 161-167 C. (dec.).

EXAMPLE 13 11 meth0xy-8,12b-dihydr0-2,8-dimethyl-12bphenyl-4H- [1,3 oxazino [3,2-d] [1,4] -benzodiazepine-4,7- 6H) -di0ne In the manner given in Example 1, 7-methoxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin 2(lH)-one in ether solution was treated with acetyl chloride in the presence of triethylamine to give 11-methoxy-8,12b-dihydro-2,8- dimethyl 12b-phenyl-4H [1,3]oxazino[3,2d] [1,4] benzodiazepine-4,7 (6H) -di0ne.

9 EXAMPLE 14 11 bromo 8,IZb-dihya'ro-2,8-dimethyl-1Zb-phenyl-4H- [1,3]xazin0[3,2-d] [1,4] benzodiazepine 4,7(6H)- dione In the manner given in Example 1, 1-methyl-7-bromo- -phenyl-3H-1,4-benzodiazepin -2 (1H)-one was treated with acetyl chloride in the presence of triethylamine to give 11 bromo-8,12b-dihydro-2,8-dimethyl-12b-phenyl- 4H [1,4]oxazino[3,2-d][1,4]benzodiazepin 4,7(6H)- dione.

EXAMPLE 15 11 iodo 8,12b-dihydro-Z-hexyl-3-penIyl-8-methyl-12bphenyl 4H [1,3]0xazino[3,2 d] [1,41benzodiazepine- 4,7(6H)-di0ne In the manner given in Example 1, 1-meth yl-7-iodo-5- phenyl-3H-1,4-benzodiazepin-2(1H)-one was treated with heptanoyl chloride in the presence of triethylamine to give 11 iodo 8,121) dihydro-2-hexyl-3-pentyl-8-methyl- 12b phenyl 4H-[1,3]oxazino[3,2-d][1,4]-benzodiazepine-4,7 6H) -dione.

EXAMPLE 16 11 fluoro 8,121) dihydro 2-ethyl-3,8-dimethyl-I2bphenyl -4H [1,310xazino [3,2-a'] [1,4]-benz0diazepine- 4,7(6H)-dime In the manner given in Example 2, 1-methyl-7-fiuoro- 5-phenyl-3H-1,4-benzodiazepin 2(1H)-one was treated with bis-(methylketene) H (CH;C=C=O)2 in acetone to give 11-fluoro-8,12b-dihydro-2-ethyl-3 ,8-dimethyl 12b-phenyl-4H- 1,4] oxazino [3,2d] [1,4] -benzo diazepine-4,7 (6H) -dione.

EXAMPLE 17 11 chloro 8,12b dihydro-8-benzyl-2-m'ethyl-12b-(3,4- dimethylphegnyl) 4h [1,3]0xazin0[3,2-d] [1,4]benz0- diazepine-4,7(6H) -di0ne In the manner given in Example 1, 1-benzyl-7-chloro- 5-(3,4 dimethylphenyl) 3H-1,4-benzodiazepin-2(1H)- one was treated with acetyl chloride in the presence of triethylamine to give 11 chloro 8,l2b-dihydro-8-benzyl-2- methyl-12b-(3,4 dimethylphenyl) 4H [1,3]oxazino [3,2-d] [1,4] benzodiazepine-4,7 6H -dione.

EXAMPLE 18 11 chloro 8,121) dihydro-2,8,9 triethyl-3-methyl-I2b- (3 bromo 4 butylphenyl)-4H-[1,3]0xazino[3,2-d] [I ,4 1 benz0diazepine-4,7 (6H )-di0ne In the manner given in Example 1, 1,9-diethy1-7-chloro- 5-(3 bromo 4 butylphenyl)-3H-1,4-benzodiazepine-2 (1H)-one was treated with propionyl chloride in the presence of triethylamine to give 11-chloro-8,12b-dihydro- 2,8,9-triethyl-3-methyl 12b (3 bromo-4-butylphenyl)- 4H [1,3]oxazino[3,2 d] [1,4]benzodiazepine-4,7(6H)- dione.

EXAMPLE 19 chloro 8,12b dihydro-Z-methyl-IZb-(p-fluorophem yl)-4H [1,3]0xazin0[3,2-d] [1,4] benzodiazepin -4 6H )-0ne-7-thi0ne In the manner given in Example 1, 1-benzyl-8-chloro-5- (p fluorophenyl) 3H 1,4 benzodiazepine-2(1H)- thione was treated with acetyl chloride in the presence of triethylamine to give 10-chloro-8,12b-dihydro-8-benzyl-2- methyl 12b-(p fluorophenyl) 4H-[1,3]oxazino[3,2- d] [1,4] -benzodiazepin-4 6H -one-7-thione.

In the manner given in Example 4B, the thus-produced 10-chloro 8,12b dihydro 8 benzyl 2 methyl 12b- (p-fiuorophenyl) 4H [1,3]oxazino[3,2 d][1,4]-benzodiaZepin-4(6H)-one-7-thione was hydrogenated in ethyl acetate in the presence of 10% palladium-on-charcoal catalyst to give 10-chloro-8,12b-dihydro-2-methyl 12b (p 10 fluorophenyl) 4H [1,3]oxazino[3,2 d][1,4]-benzodiazepin-4(6H)-one-7-thione.

EXAMPLE 20 11 nitro 8,1212 dihydro 2,8 dimethyl-IZb-(o fluoro phenyl) 4H-[1,3]0xazin0[3,2-d []1 ,41benzodz'azepine- 4,7(6H)-drone A mixture of 0.78 g. (2.5 mmoles) of 5 (o-fiuorophenyl) 1,3 dihydro 1 methyl-7-nitro-2H-1,4-benzodiazepin-Z-one and 10 g. of diketene was heated on the steambath for 1 hour. The reaction mixture was poured on a silica gel column (100 g.) and eluted with 50% ethyl acetate-cyclohexane:

Ml. Product;

Fraction Number:

50 Diketene. 1 25 Do.

25 0.432 g. of starting material.

1 25 0.255 g. of desired product.

EXAMPLE 21 11 chloro 8,12b dihydro 2-is0butyl-3-is0propyl-8- methyl 12b phenyl 4H-[1,3]0xazi n0[3,2d] [1,4] benz0diazepine-4,7( 6H )-di0ne A solution of 9 g. (0.075 mole) of isovaleryl chloride in 20 ml. of ether was added during 20 minutes to a solution of 0.7 g. 2.5 mmole) of 7-chloro-1-methyl-5-phenyl- 3H-1,4-benzodiazepin-2(1H)-one and triethylamine (15 g., 0.15 mole) in 50 ml. of ether, keeping the temperature at 20 C. The mixture was stirred at room temperature overnight. It was cooled in ice, 20 ml. of water was added, the organic layer was separated and washed with water (3x25 ml.), 25 ml. of saturated salt solution, dried over anhydrous magnesium sulfate and evaporated to give a residue. The residue (5.3 g.) was chromatographed on 100 g. of silica gel using 40% ethyl acetate-cyclohexane as the eluant; 20-ml. fractions were collected. Fractions 1-6 were discarded. Fractions 7-9 were combined (0.965

g.) and rechromatographed on 100 g. of silica gel exactly as described above. Fractions 710 were combined to give 0.74 g. (66%) of 11-chloro-8,12b-dihydro-2-isobutyl- 3 isopropyl 8 methyl 12b-phenyl-4H-[1,3]oxazino [3,2-d] [1,4]benzodiazepine-'4,7(6H)-dione as an oil.

U.V.: max. 224 (18,400); sh. 272 (4450). Analysis.Cald. for C H ClN O (percent): C,

68.94; H, 6.45; CI, 7.83; N, 6.19. Found (percent): C,

68.86; H, 6.81; Cl, 7.5; N, 6.00.

EXAMPLE 22 1] chloro 8 (cyclopropylmethyl) 8,12b-d1'hydr0-2- methyI-IZb-phenyl 4H [1,3]0xazin0[3,2 d] [1,4] benzodiazepine-4,7( 6H -dz'0ne A mixture of 0.81 g. (2.5 mmoles) of 7 chloro-1- (cyclopropylmethyl) 5 phenyl 3H-1,4-benzodiazepin- 2(1H)-one and 10 g. of diketene was heated at C.

for 45 minutes. The solution was evaporated in vacuo,

and the resulting oily solid was triturated with 10 ml. of

cold methanol. The solid was filtered, washed with 2 ml.

of cold methanol, then with ether (2X5 ml.) to give 0.668 g. (66%) of 11 chloro 8-(cyclopropylmethyl)- 8,12b dihydro 2 methyl 12b-phenyl-4H-[1,3] oxazino[3,2 d][1,4]benzodiazepine 4,7 (6H) dione of melting point 185-186 C. (dec.), a tranquilizer like those of Formula II.

U.V.: A max. 243 (17,150).

Analysis.-Calcd. for C H ClN O (percent): C, 67.56; H, 5.18; Cl, 8.67; N, 6.85. Found (percent): C, 67.64; H, 5.22; Cl, 8.69; N, 6.59.

EXAMPLE 23 11 chloro 8,12b dihydro 6 methoxy-2,8-dimlethyl- 12b phenyl 4H [1,3]xazin0[3,2 d] [1,4 benz0- diazepine-4,7(6H)-dione A mixture of 0.7 g. (0.00227 mole) of 7-ch1oro-1-methyl 3 methoxy phenyl 3H-1,4-benzodiazepin- 2(1H)-one [S. C. Bell et al., J. Med. Chem., 11, 457 (1968)] and 10 g. of diketene was heated at 96 C. for 1.5 hours to give 130 mg. of 11-ch1oro-8,12b-dihydro-6- methoxy-2,8 dirnethyl 12b phenyl 4H [1,3] oxazino-[3,2 d] [1,4]benzodiazepine 4,7(6H) dione of melting oint 158-160 C.

U.V.: 71 max. 244 (18,500).

Analysis.--Calcd. for C H ClN O (percent): C, 63.24; H, 4.80; Cl, 8.89; N, 7.03. Found (percent): C, 63.21; H, 5.16; Cl, 8.86; N, 6.61.

EXAMPLE 24 11 chloro 8,12b dihydro 2 methyl-12b-phenyl-4H- [I,3]oxazino[3,2 d] [1,4]benz0diazepine 4,7(6H)- dione A mixture of 0.675 g. (2.5 mmoles) of 7-chloro-5- phenyl 3H 1,4 benzodiazepin 2(1H)-one and 10 g. of diketene was heated on the steam bath for 1 hour to give 0.252 g. of 11 chloro-8,12b-dihydro-2-methy1-12bphenyl 4H [1,3]0xazino[3,2-d] [1,4]benzodiazepinev 4,7(6H)-dione of melting point 173 C. with effervescence.

U.V.: A max. 204 (35,850); 243 (17,800); sh. 290 (1650); sh. 305 (663).

Analysis.Calcd. for C H ClN O (percent): C, 64.32; H, 4.26; Cl, 9.99; N, 7.90. Found (percent): C, 64.79; H, 4.90; CI, 9.81; N, 7.37.

EXAMPLE 25 In the manner given in Example 2, but in the absence of solvent, 0.85 g. of 7-chloro-1,3-dihydro-5 (o fluorophenyl)1-methyl-2H-1,4-benzodiazepin-2-one was treated with 10 g. of diketene on the steam bath under nitrogen for 2 hours to give 0.32 g. (30%) of 1l-chl0ro-l2b-(0- fluoropheny1)-8,1Zb-dihydro-2,8-dimethyl-4H 1,3 oxazino[3,2-d][1,4]benzodiazepine-4,7(6H)-dione of melting point 175-177 C.

U.V.: (Ethanol): 203 (38,550): s1. sh. 228 (18,000); 238 (17,850); s1. sh. 263 (7,000); sh. 269 (4,600).

Analysis.-Calcd. for C H ClFN o (percent): C, 62.10; H, 4.17; N, 7.24; CI, 9.16; F, 4.91. Found (percent): C, 62.01; H, 4.71; N, 7.14; CI, 9.17; F, 4.54.

EXAMPLE 26 11-chl0r0-8,12b=dihydro-2,8-dimethyl 12b (0 chlorophenyl 4H- [1,3] oxazino [3,2 d] [1,41benzodiazepine- 4,7(6H) dione In the manner given in Example 2, but in the absence of solvent, 0.80 g. of 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-1methyl-ZH-1,4-benzodiazepin-2 one was reacted with 10 g. of diketene on the steam bath under nitrogen for 19 hours to give 11-chloro-8,12b-dihydro-2,8-dimethyl- 12b-(o-chlorophenyl) 4H [1,3]oxazino[3,2 d][1,4] benzodiazepine-4,7(6H)-dione.

In the manner given in the preceding examples, other oxazinobenzodiazepinones of Formula II can be prepared from the corresponding benzodiazepinones by 12 treating such benzodiazepinones with a diketene or a diketene-producing reagent (acylhalide and triethylamine). Representative compounds of this type include:

1 l-chloro- 8, 12b-dihydro-2-pentyl-3 butyl-12b-phenyl-4H- [1,3 oxazino 3,2-d] [1,4] benzodiazepine-4,7 6H) dione;

9-methoxy-l 1-diode-8,12b-dihydro-2-heptyl-3 hexyl-12b- (3,4-dimethylphenyl) 4H- 1,3 oxazino [3,2-d] 1,4] benzodiazepine-4,7 6H) dione;

12- chloro-S 12b-dihydro-2-methyl-8-propy1-12b-phenyl- 4H-[1,3]oxazino[3,2-d] [1,4]benzodiazepine-4,7 6H) dione;

IO-trifluoromethyl-S ,12b-dihydro-2, 8-dimethyl-12b-(pbromophenyl)-4H-[1,3]oxazino[3,2-d] [1,4] benzodiazepine-4,7 6H) dione 9 bromo-8,12b-dihydro-2,8-diethyl-3methyl-12b-(p tolyl 4H 1,3 1 oxazino 3,2-d] 1,4] benzodiazepine-4,7 (6H) dione;

10-nitro-8,1Zb-dihydro-2-propyl-3-ethy1-12b-pheny1-4H- [1,3 oxazino 3,2-d] [1,4] benzodiazepine-4,7 (6H) dione;

1 1-nitro-8,12b-dihydro-2,8-dibutyl-3-propyl-12b-(p-trifiuoromethy1phenyl)-4H-[ 1,3 oxazino [3 ,2-d] 1,4] benzodiazepine-4,7 6H) dione;

9-methyl-1 O-nitro- 8 12b-dihydro-2-methy1-8-benzy1-12b- 3 ,4- (diethoxyphenyl) -4H-[ 1,3 oxazino[3,2-d] [1,4] benzodiazepine-4,7 6H) dione;

12bromo-9-butoxy-8, 12b-dihydro 2-hexyl-3 pentyl- 8- benzyl-12b-(p-chlorophenyl)-4H- 1,3 ]oxazino [3 ,2-d]

[ 1,4] benzodiazepine-4,7 6H) dione;

1 l-chloro-12-nitro-8,1'2b-dihydro-6-methoxy-2-methyl- 12b- (m-bromophenyl) 4H- 1,3 oxazino [3 ,2-d] [1,4] benzodiazepine-4,7 6H) dione;

1 l-bromo- 8 1 Zb-dihydro-6-ethoxy-2-propyl-3 ethyl- 8- benzyl-12b-(p-chlorophenyl) -4H- 1,3 oxazino [3,2-d]

[1,4]'benzodiazepine-4,7 6H) dione;

9-methyl-8,12b-dihydro-2,6, 8-triethyl-3-methyl-12b-(pi0d0pheny1)-4H- 1,3 oxazino [3 ,2-d] 1,4] benzodiazepine-4,7 6H) dione;

10-cyano-8,12b-dihydro-2-methyl-6,8-dibutyl-12b-phenyl- 4H-[1,3 ]oxazino[3 ,2-d] [1,4] benzodiazepin-4 6H one-7-thione 9-cyano-8,12b-dihydro-2-butyl-3propyl-S-benzyl-12b-(mbutylphenyl) 4H- 1,3 oxazino [3 ,2-d] [1,4] benzodiazepine-4 (6H one-7-thione;

[ 1,4] benzodiazepin-4 (6H) one-7-thione, and the like.

I claim: 1. An oxazinobenzodiazepine of the Formula II:

B4 II consisting of hydrogen, alkyl defined as above, and phenyl.

2. The compound of claim 1 wherein R is ll-chloro, R R R R and R are hydrogen, R is methyl and R 13 is oxygen, and the compound is thus 11-chloro-8,l2b-dihydro-2,8-dimethyl-12b-phenyl-4H- 1,3 ]oxazi.no [3,2 d] [1,4] benzodiazepine-4,7 6H dione.

3. The compound of claim 1 wherein R is 11-chloro-, R R R and R are hydrogen, R is methyl, R is oxygen and R is phenyl, and the compound is thus ll-chloro- 8,12b-dihydro-2-benzy1-3,l2b-diphcnyl-8-methyl-4H [1, 3 oxazino [3,2-d] [1,4] benzodiazepine-4,7 (6H dione.

4. The compound of claim 1 wherein R is 11-chloro-, R R R R R and R are hydrogen and R is oxygen, and the compound is thus 1l-chloro-8,l2b-dihydro-2- methy1-12b-phenyl-4H-[1,3]oxazino [3,2 d][l,4]benzdiazepine-4,7 6H) -dione.

5. The compound of claim 1 wherein R is ll-trifluoromethyl, R R R R and R are hydrogen, R is methyl and R is oxygen, and the compound is thus ll-trifiuoromethyl-8,l2b-dihydro-2,8-dimethyl-12b-phenyl-4H [1,3] oxazino 3,2-d] [1,4] benzodiazepine-4,7 6H) dione.

6. The compound of claim 1 wherein R is 1l-chloro-, R is p-chloro, R R R and R are hydrogen, R is methyl and R is oxygen, and the compound is thus 11- chloro-S,12b-dihydro-2,8-dimethyl 12b (p chloropheny1)-4H [1,3]oxazino[3,2 d][1,4]benzodiazepine- 4,7(6H)-dione.

7. The compound of claim 1 wherein R is 11-chloro-, R R R R and R are hydrogen, R is methyl and R is sulfur, and the compound is thus 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4H- 1,3 oxazino[ 3 ,2 d]

[1,4]benzodiazepin-4 6H one-7-thione.

8. The compound of claim 1 wherein R is ll-cyano, R R R R, and R are hydrogen, R is methyl and R is oxygen, and the compound is thus l1-cyano-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4H-[l,3]oxazino[3,2 d]

[ 1,4] -benzodiazepine-4,7 6H) dione.

9. The compound of claim 1 wherein R is ll-chloro, R R R and R are hydrogen, R is methyl, R is oxygen and R is ethyl, and the compound is thus 11- chloro-8,l2b dihydro 3-ethyl-84methyl-2-propyl-12bphenyl 4H [1,3]oxazino[3,2-d][1,4]benzodiazepine- 4,7(6H)-dione.

10. The compound of claim 1 wherein R is ll-chloro, R R R and R are hydrogen, R and R are methyl and R is oxygen, and the compound is thus ll-chloro- 8,l2b-dihydro-2-ethyl-3,8-dimethyl 12b phenyl 4H- [1,3]oxazino[3,2d][l,4]benzodiazepine 4,7(6H) dione.

11. The compound of claim 1 wherein R R R R R and R are hydrogen, R is methyl and R is oxygen, and the compound is thus 8,12b-dihydro-2,8 dimethyl-lZbphenyl 4H [1,3]oxazino[3,2-d][1,4]-benzodiazepine- 4,7(6H)-dione.

12. The compound of claim 1 wherein R is ll-nitro, R R R and R are hydrogen, R is o-fluoro, R is methyl and R is oxygen, and the compound is thus 11- nitro-8,12b-dihydro-2,8-dimethyl-12b (o-fluorophenyl)- 4H [1,3]oxazino[3,2-d][1,4]benzodiazepine 4,7(6H)- dione.

13. The compound of claim 1 wherein R is ll-nitro, R R R R and R are hydrogen, R is methyl, R is oxygen and R is phenyl, and the compound is thus 11- nitro-8,l2b-dihydro 2,8-dimethyl-12b-phenyl-4H-[1,3]- oxazino 3,2-d] [1,4] -benzodiazepine-4,7 (6H dione.

14. The compound of claim 1 wherein R is ll-chloro, R R R and R are hydrogen, R is methyl and R is oxygen, R is isopropyl and' the compound is thus 11- chloro-8,12b-dihydro-2-isobutyl-3isopropyl 8 methyll2b-phenyl 4H-[1,3]oxazino[3,2-d] [1,41benzodiazepine- 4,7(6H)-dione.

15. The compound of claim 1 wherein R is ll-chloro, R R R and R are hydrogen, R is methyl and R is oxygen, and R is methoxy, and the compound is thus ll-chloro 8,12-b-dihydro 6-meth0Xy-2,8-dimethyl- 12b phenyl-4H-[1,3]oxazino[3,2-d] [1,4]benzodiazepine- 4,7(6H)-dione.

16. The compound of claim 1 wherein R is ll-fluoro,

R R R and R are hydrogen, R and R are methyl, and R is oxygen, and the compound is thus ll-fluoro- 8,12b-dihydro-2-ethyl 3,8 dimethyl 12b-phenyl-4H- [1,3]0xazino[3,2-d][1,4]benzodiazepine 4,7(6H) dione.

17. The compound of claim 1 wherein R is ll-chloro, R R R and R are hydrogen, R is o-fiuoro, R is methyl and R is oxygen and the compound is thus 11- chloro 8,12b dihydro 2,8 dimethyI-IZb-(o-fluorophenyl) 4H [l,3]oxazino[3,2-d][1,4]benzodiazepine- 4,7(6H)-dione.

18. The compound of claim 1 wherein R is ll-chloro, R R R and R are hydrogen, R is o-chloro, R is methyl and R is oxygen, and the compound is thus 11- chloro-8,l2b-dihydro-2,8 dimethyl 12b (o-chlorophenyl) 4H [l,3]oxazino[3,2-d][l,4]benzodiazepine- 4,7 6H dione.

19. ll chloro 8 (cyclopropylmethyl)-8,l2b-dihydro-2 methyl 12b phenyl-4H-[l,3]oxaz.ino-[3,2-d]- 1,4] -benzodiazepine-4,7 6H dione.

20. A process for the production of an oxazinobenzodiazepine of the Formula 11:

wherein R R R and R are selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, inclusive alkoxy of 1 to 6 carbon atoms, inclusive, halogen, CF3, NO and CN; wherein R is selected from the group consisting of hydrogen and alkyl defined as above, and benzyl; wherein R is selected from the group consisting of =0 and :8; wherein R is selected from the group consisting of hydrogen, alkyl defined as above, and alkoxy as defined above; and wherein R is selected from the group consisting of hydrogen, alkyl defined as above, and phenyl, which comprises: treating, in an inert organic solvent, 21 5 phenyl-3H-1,4-benz0diazepin- 2(lH)-one of the Formula 1:

wherein R R R R R R 'and R are defined as above, with a diketene of the formula wherein R is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, inclusive, and phenyl.

21. The process of claim 20 wherein 7-chloro-1-methyl- 5-phenyl-3-H-l,4 benzodiazepin 2(lH) one is reacted with di ketene in acetone to give 11-chloro-8,l2b-dihydro- 2,8-dimethyl 12b phenyl 4H [l,3]oxazino[3,2-d]- [1,4] benzodiazepine-4,7(6H)dione.

22. The process of claim 20 wherein a diketene is produced in situ by the reaction of an acyl halide selected from the group consisting of chlorides and bromides of alkanoic acids of 2 to 8 carbon atoms, inclusive, and phenylsubstituted alkanoic acids of 8 to 10 carbon atoms,

15 inclusive, which have at least two hydrogen atoms in the 2- position, in the presence of an acid acceptor.

23. The process of claim 22 wherein the acyl halide is acetyl chloride.

24. The process of claim 22 wherein the acyl halide is phenylacetyl chloride.

25. The process of claim 23 wherein 7-chloro-1-rnethyl- 5-phenyl-3H-1,4-benzodiazepin 2(1H) one is reacted with acetyl chloride and triethylamine in ether to give 11-chloro-8,12b-dihydro-2,8-dimethyl-12b phenyl 4H- [1,3]oxazino[3,2-d][1,4] benzodiazepine 4,7(6H)-dione.

16 References Cited UNITED STATES PATENTS 3,483,187 12/1969 Doebel et a1.

US. Cl.

Patent No. 3,575,282 D t d June 21, 1971 In nt Jacob Szmuszkovicz It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 5, l lne 24, for "85 m./l g." read 85 mg/kg Column 4, l ine 47, for "lmethyl" read 1-methyl-- Column l ine 18, for "(p-ch loropheny l read (p-ch lorophenyl l lne 28, for "100 C. read 100 C. l i ne '5, for "sh 25 read sh 245 Column 8, l ine 24, for "benzodiazepim" r benzod i azepi nel ine 55 for "C H Cl 0 read C H ClN 0 Column 9, l ine 10, for "benzodiazeplm" re benzodiazepi nel ine 58, for "-4h" read +H- Column 10, l ine 6, for "[5,2-d j1, lJ" read |'5,2-dj [1A] l l ne 58, f0!" "C23H21 O3 2" read C H Cl N203 l ine 6O for 1 7 5" r d Cl 7 .75 Column 11, l ine l, for

I C12H21 C l N203 read C23H2-1 ClNgOg 2 l ine 10, f0! [1 lread [1, l |ben Column 12 l ine 7, for"11d lode" read lliodo l ine 29, for (p-ch lorophenyl read (p-propylp Column l l, l ine 22, for formu la 11" read formu la l l l i ne +6 for formu la 1" read formu la I Signed and sealed this 16th day of November 1971 (SEAL) Attest:

EDWARD M.F'LETCHER,JR. ROBERT GOTTSCHALK Attosting Officer Acting Commissioner of Patent: 

